When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

Packaged-food giant ConAgra is planning to label some of its Healthy Choice frozen meals "GLP-1 friendly" in an effort to respond to the effect that the obesity drugs, made by Novo Nordisk, Eli Lilly ...

Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered ...

PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer ...

Alphabet could benefit from the growth of AI and cloud computing for years, especially considering the company's competitive ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

The Harbor Diversified International All-Cap Fund performed broadly in line with its benchmark, the MSCI All Country World Ex ...

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...